These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32294306)

  • 1. Potential of fosfomycin in treating multidrug-resistant infections in children.
    Williams PC
    J Paediatr Child Health; 2020 Jun; 56(6):864-872. PubMed ID: 32294306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin in antimicrobial stewardship programs.
    Múñez Rubio E; Ramos Martínez A; Fernández Cruz A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):62-66. PubMed ID: 31131594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New microbiological aspects of fosfomycin.
    Díez-Aguilar M; Cantón R
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):8-18. PubMed ID: 31131587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment.
    Folgori L; Bielicki J; Heath PT; Sharland M
    Curr Opin Infect Dis; 2017 Jun; 30(3):281-288. PubMed ID: 28306563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
    Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New ways of using old antibiotics in pediatrics: Focus on fosfomycin.
    Tran MT
    Pharmacotherapy; 2023 Jul; 43(7):705-712. PubMed ID: 36825460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.
    Falagas ME; Kastoris AC; Kapaskelis AM; Karageorgopoulos DE
    Lancet Infect Dis; 2010 Jan; 10(1):43-50. PubMed ID: 20129148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JMM Profile: Fosfomycin: a potential antibiotic for multi- and extensively resistant bacteria.
    Wangchinda W; Rattanaumpawan P
    J Med Microbiol; 2022 Aug; 71(8):. PubMed ID: 35951643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
    Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
    Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revival of old antibiotics: needs, the state of evidence and expectations.
    Zayyad H; Eliakim-Raz N; Leibovici L; Paul M
    Int J Antimicrob Agents; 2017 May; 49(5):536-541. PubMed ID: 28162982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens.
    Ruiz Ramos J; Salavert Lletí M
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):45-54. PubMed ID: 31131592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.